Our health care roundtable gathers the Motley Fool's top health care analysts to discuss the sector's biggest stories in a free flowing and highly opinionated format.
In this segment, the analysts discuss how Abbott Labs is spinning off its branded pharmaceutical department at the end of the year to allow the new company, AbbVie, to steward the care of the company's biggest revenue driver, Humira, which exposes it to a lot of "all your eggs in one basket" risk. But could Johnson & Johnson face similar risks one day? What are the other departments within JNJ are facing headwinds at the moment?
With the impending spinoff of its branded-drug business, Abbott Labs is losing a massive blockbuster drug in Humira. It's a confusing event to understand, with many investors left wondering what to do with these two stocks once they're separated. To help investors better understand the upcoming event, the Fool has created a brand new premium report outlining both Abbott Labs and its spinoff, AbbVie. Inside, we outline all of the must-know opportunities and risks facing both companies, so make sure to claim this 2-for-1 report by clicking here now.
The article Analyst Roundtable: Big Pharma Spinoffs originally appeared on Fool.com.
Brenton Flynn has no positions in the stocks mentioned above. David Williamson owns shares of Pfizer. The Motley Fool owns shares of Johnson & Johnson. Motley Fool newsletter services recommend Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.